Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Jason Aryeh sold 6,330 shares of the company’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $105.28, for a total transaction of $666,422.40. Following the transaction, the director now owns 58,959 shares of the company’s stock, valued at approximately $6,207,203.52. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) traded up 0.6820% during midday trading on Monday, reaching $106.4712. 128,609 shares of the company were exchanged. The company has a market capitalization of $2.23 billion, a PE ratio of 305.0751 and a beta of 1.43. Ligand Pharmaceuticals Inc. has a 52-week low of $82.06 and a 52-week high of $139.79. The firm’s 50 day moving average is $98.21 and its 200-day moving average is $112.79.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its earnings results on Thursday, November 3rd. The biotechnology company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.03. The company had revenue of $21.62 million for the quarter, compared to analysts’ expectations of $23.64 million. Ligand Pharmaceuticals had a return on equity of 9.98% and a net margin of 8.51%. The firm’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same period last year, the business posted $0.57 earnings per share. On average, equities analysts forecast that Ligand Pharmaceuticals Inc. will post $3.40 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

A number of equities analysts have commented on the stock. CJS Securities cut their price objective on shares of Ligand Pharmaceuticals from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Wednesday, September 28th. TheStreet downgraded shares of Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 7th. Roth Capital set a $154.00 price objective on shares of Ligand Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, October 28th. Craig Hallum upped their price objective on shares of Ligand Pharmaceuticals from $150.00 to $160.00 in a research report on Wednesday, October 5th. Finally, Zacks Investment Research upgraded shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 9th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $139.70.

A number of large investors have recently bought and sold shares of LGND. BlackRock Inc. boosted its stake in Ligand Pharmaceuticals by 165.1% in the first quarter. BlackRock Inc. now owns 1,381 shares of the biotechnology company’s stock worth $147,000 after buying an additional 860 shares during the last quarter. State Street Corp boosted its stake in Ligand Pharmaceuticals by 10.1% in the first quarter. State Street Corp now owns 699,788 shares of the biotechnology company’s stock worth $74,940,000 after buying an additional 64,410 shares during the last quarter. Geode Capital Management LLC boosted its stake in Ligand Pharmaceuticals by 2.1% in the first quarter. Geode Capital Management LLC now owns 131,624 shares of the biotechnology company’s stock worth $14,095,000 after buying an additional 2,653 shares during the last quarter. Barclays PLC boosted its stake in Ligand Pharmaceuticals by 719.3% in the first quarter. Barclays PLC now owns 9,070 shares of the biotechnology company’s stock worth $971,000 after buying an additional 7,963 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in Ligand Pharmaceuticals by 134.9% in the second quarter. BNP Paribas Arbitrage SA now owns 5,920 shares of the biotechnology company’s stock worth $706,000 after buying an additional 3,400 shares during the last quarter.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

5 Day Chart for NASDAQ:LGND

Receive News & Stock Ratings for Ligand Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.